Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report)'s share price rose 7.8% on Tuesday . The company traded as high as $3.23 and last traded at $3.17. Approximately 431,762 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 810,920 shares. The stock had previously closed at $2.94.
Wall Street Analysts Forecast Growth
Separately, Cormark upgraded shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, Curaleaf has a consensus rating of "Strong Buy".
View Our Latest Analysis on Curaleaf
Curaleaf Stock Performance
The company has a market capitalization of $1.61 billion, a PE ratio of -7.52 and a beta of 0.78. The company has a current ratio of 1.47, a quick ratio of 0.70 and a debt-to-equity ratio of 1.00. The firm's 50-day simple moving average is $2.10 and its 200-day simple moving average is $1.31.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%. On average, research analysts predict that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Further Reading
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.